In 2011, Dr. Yi Rang Kim met Dr. Jin Woo Choi in Massachusetts General Hospital. Dr. Kim was a
Ph.D. candidate and Mr. Choi was a postdoc. They met as a physician and biologist discussing
basic research and the deficiencies in research and clinical research. They promised to work
together someday because they could fill each other's gaps if they worked together later. After
receiving a doctorate in KAIST, Dr. Kim finished his medical training in oncology. Meanwhile,
Dr. Choi became a professor of pharmacology in Kyunghee University. Dr.Kim felt sorry for the
patients who could not receive treatment due to the high cost of the drugs or their deficiency
and discussed with Mr. Choi how to solve the problem. Then, they founded Oncocross.
Oncocross has strived for discovering drugs that can satisfy unmet needs in numerous diseases
and medical conditions. While treating cancer patients, a number of patients complained about sar-
copenia and Oncocross has developed the sarcopenia drugs which are one of our pipelines. These
safe sarcopenia drugs also expand ALS survival significantly. In this way, we will continue to find
safe and effective drugs. Oncocross will do its best until all the patients are happy.
BI Team Leader
AI Team Leader
is a prefix that means tumor.
represents our technology and commitment to develop new drugs using convergent sciences.